Prosecution Insights
Last updated: October 25, 2026
Application No. 18/922,987

DIGITAL THERAPY MANAGEMENT SYSTEM OF REFLECTING AND UPDATING FEEDBACK ACCORDING TO ACTUAL USE OF DIGITAL THERAPEUTICS AND OPERATION METHOD THEREOF

Non-Final OA §101
Filed
Oct 22, 2024
Priority
Jan 31, 2024 — RE 10-2024-0014816
Examiner
MPAMUGO, CHINYERE
Art Unit
3685
Tech Center
3600 — Transportation & Electronic Commerce
Assignee
Odn Co. Ltd.
OA Round
3 (Non-Final)
29%
Grant Probability
At Risk
3-4
OA Rounds
1y 8m
Est. Remaining
56%
With Interview

Examiner Intelligence

Grants only 29% of cases
29%
Career Allowance Rate
101 granted / 350 resolved
-23.1% vs TC avg
Strong +27% interview lift
Without
With
+26.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
30 currently pending
Career history
387
Total Applications
across all art units

Statute-Specific Performance

§101
39.8%
-0.2% vs TC avg
§103
36.8%
-3.2% vs TC avg
§102
11.3%
-28.7% vs TC avg
§112
11.2%
-28.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 350 resolved cases

Office Action

§101
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims In the response dated August 10, 2026, Applicant amended claims 1 and 9. Claims 2 and 10 were canceled, and claims 4, 7, and 12 were previously canceled. Claims 1, 3, 5, 6, 8, 9, 11, and 13-17 are pending in the current application. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on August 10, 2026, has been entered. Information Disclosure Statement The information disclosure statement (IDS) received on September 6, 2026, has been considered by examiner. Response to Arguments Applicant's arguments with respect to the rejection under 35 U.S.C. 101 have been fully considered but they are not persuasive. First, applicant asserts that the claims do not fall into the mental processes grouping because the claims require bio-signal data of a user continuously monitored through multimodal sensor and feedback information providing processor to dynamically adjust and control the system environment, which requires physical reconfiguration of hardware parameters and continuous real-time monitoring that cannot be performed by the human mind. Examiner respectfully disagrees. Using the broadest reasonable interpretations, the claims encompass a user (e.g., medical professional) collecting prescription information from a medical institution, evaluating said information (e.g., by reading or reviewing a document), and providing feedback information based on the evaluation or performing a mental process. The aforementioned limitations encompass observation and evaluation of medical equipment. Medical professionals evaluate and observe multiple bio-signals and identify patterns to determine the appropriate treatment for a patient. The use of equipment does not prevent the claims from being in the Mental Processing abstract idea grouping. Claims can recite a mental process even if they are claimed as being performed on a computer. In Benson, The Court determined that a mathematical algorithm for converting binary coded decimal to pure binary within a computer’s shift register was an abstract idea. The Court concluded that the algorithm could be performed purely mentally even though the claimed procedures "can be carried out in existing computers long in use, no new machinery being necessary." Thus, the claims recite a mental process. Second, Applicant asserts that the claims are eligible under Desjardins and recite a particular closed-loop technological solution. Examiner respectfully disagrees. To evaluate improvements, the specification should be evaluated to determine if the disclosure provides sufficient details such that one of ordinary skill in the art would recognize the claimed invention as providing an improvement. If the specification sets forth an improvement in technology, the claim must be evaluated to ensure that the claim itself reflects the disclosed improvement. In this case, Applicant’s specification discloses, “the use of the multimodal sensor may enable a more comprehensive assessment of the user's health status, and provision of information on environmental factors in addition to bio-signals. This provides healthcare professionals with a richer context to help develop patient-centered treatment approaches and ultimately improve patient health and well-being.” Applicant specification also discloses improved user experience, effectiveness of treatment maximized, improving the effectiveness of digital treatment through continuous monitoring and analysis and providing treatment optimized for the patient's health condition. These improvements are not technological in nature, rather they are improvements in patient care. Moreover, in Desjardins, where solving a concrete technical problem like catastrophic forgetting improves computer functionality. In this case, the claims encompass a user (e.g., medical professional) collecting prescription information from a medical institution, evaluating said information (e.g., by reading or reviewing a document), and providing feedback information based on the evaluation. “continuously monitoring bio-signals” and “dynamically adjusting equipment parameters” can be achieved through observation and evaluation of the patient or equipment attached to the patient. As for the accompanying Declaration, please review the next section below. Last, Applicant asserts that the claims recite significantly more than the abstract idea and are not well-understood, routine, or conventional under step 2B because of the withdrawal of the prior art rejection. Examiner respectfully disagrees. Lack of novelty under 35 U.S.C. 102 or obviousness under 35 U.S.C. 103 of a claimed invention does not necessarily indicate that additional elements are well-understood, routine, conventional elements. Because they are separate and distinct requirements from eligibility, patentability of the claimed invention under 35 U.S.C. 102 and 103 with respect to the prior art is neither required for, nor a guarantee of, patent eligibility under 35 U.S.C. 101 (see MPEP 2106.05 (I)). As stated above, the terminal and database are recited at a high-level of generality such that it amounts to no more than mere instructions to apply the exception using a generic computer component. The rejection is maintained. Affidavit or Declaration Under 37 CFR 1.132 The Declaration under 37 CFR 1.132 filed August 10, 2026 is insufficient to overcome the rejection of claims 1, 3, 5, 6, 8, 9, 11, and 13-17 based upon 35 U.S.C. 101 as set forth in the last Office action because the declaration fails to show that the claims are not directed to a judicial exception (i.e., a law of nature, natural phenomenon, or abstract idea) without significantly more. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1, 3, 5, 6, 8, 9, 11, and 13-17 are rejected under 35 U.S.C. 101 because the claims are not directed to patent eligible subject matter. Claims 1, 3, 5, 6, 8, 9, 11, and 13-17 do fall within at least one of the four categories of patent eligible subject matter because the claims recite a machine (i.e., system) and process (i.e., a method). Although claims 1, 3, 5, 6, 8, 9, 11, and 13-17 fall under at least one of the four statutory categories, it should be determined whether the claim wholly embraces a judicially recognized exception, which includes laws of nature, physical phenomena, and abstract ideas, or is it a particular practical application of a judicial exception (See MPEP 2106 I and II). Claims 1, 3, 5, 6, 8, 9, 11, and 13-17 are directed to a judicial exception (i.e., a law of nature, natural phenomenon, or abstract idea) without significantly more. Part I: Step 2A, Prong One: Identify the Abstract Idea Under step 2A, Prong One of the Alice framework, the claims are analyzed to determine if the claims are directed to a judicial exception. MPEP §2106.04(a). The determination consists of a) identifying the specific limitations in the claim that recite an abstract idea; and b) determining whether the identified limitations fall within at least one of the three subject matter groupings of abstract ideas (i.e., mathematical concepts, mental processes, and certain methods of organizing human activity). The identified limitations of independent claim 9 (representative of independent claim 1) recite providing prescription information generated by a medical institution terminal to a user terminal; collecting, from the user terminal, implementation result information generated according to actual use of one or more digital therapeutics based on the prescription information, the implementation result information including a user input data and bio-signal data of a user that is continuously monitored through a multimodal sensor of the user terminal; tracking effectiveness, side effects, and individual responses of the one or more digital therapeutics in real-time; providing the implementation result information to the medical institution terminal, and transmitting the tracked effectiveness, side effects, and individual responses to the medical institution terminal; analyzing and evaluating the collected implementation result information by: identifying data patterns, trends, and statistical indicators by using machine learning and pattern recognition algorithm to track performance of the one or more digital therapeutics, and using the identified data patterns, trends, and statistical indicators to train predictive models configured to predict effective combination of the one or more digital therapeutics and potential side effects for a specific user or a group of users to optimize effective treatment plan for the specific user or the group of users; generating feedback information based on the analyzed and evaluated result; and providing the generated feedback information to an input-side system environment required to generate the one or more digital therapeutics or an output-side system environment providing a physical hospital service or a virtual hospital service that supports the actual use of the one or more digital therapeutics; dynamically adjust and control a corresponding system environment according to the actual use of the one or more digital therapeutics to improve accuracy and efficiency of data collection, and optimize treatment plans and effectiveness of the one or more digital therapeutics, wherein the dynamically adjusting and controlling comprises dynamically adjusting at least one setting of at least one device among the multimodal sensor, VR/AR equipment, and wearable device used to collect user information as the input-side system environment, the at least one setting including a sensitivity of a specific sensor of the multimodal sensor, a resolution, field of view, and audio settings of the VR/AR equipment utilized in the virtual hospital service, and sensitivity, cycle, and sensor activation of the wearable device; receiving treatment result information corresponding to the implementation result information from the medical institution terminal; and updating the received treatment result information in electronic medical record (EMR) database, wherein the EMR database is configured to: collect and manage EMR data of a plurality of medical institutions, collect personal health record (PHR) data of the user, and provide remote access to the EMR data and the PHR data in real-time, allowing the plurality of medical institutions and the user terminal to simultaneously view and share necessary data and information, and wherein the digital therapy management system is linked with the medical institution terminal and the user terminal through at least one of an application service and an IoT-enabled web service via a smart terminal or an IoT terminal equipped in the medical institution terminal and the user terminal. The identified limitations, under their broadest reasonable interpretation, cover performance of the limitations in the mind (including observation, evaluation, judgement or opinion) but for the recitation of generic computer components. That is, other than the terminal and database, nothing in the claim elements precludes the steps form practically being performed in the mind. For example, the identified limitations encompass a user (e.g., medical professional) collecting prescription information from a medical institution, evaluating said information (e.g., by reading or reviewing a document), and providing feedback information based on the evaluation. The claim limitations fall within the Mental Processes groupings of abstract ideas. Thus, the claimed invention recites a judicial exception. Part I: Step 2A, prong two: additional elements that integrate the judicial exception into a practical application Under step 2A, Prong Two of the Alice framework, the claims are analyzed to determine whether the claims recite additional elements that integrate the judicial exception into a practical application. In particular, the claims are evaluated to determine if there are additional elements or a combination of elements that apply, rely on, or use the judicial exception in a manner that imposes a meaningful limit on the judicial exception, such that the claims are more than a drafting effort designed to monopolize the judicial exception. This judicial exception is not integrated into a practical application. The terminal and database are recited at a high-level of generality such that it amounts to no more than mere instructions to apply the exception using a generic computer component. Accordingly, this additional element does not integrate the abstract idea into a practical application because it does not impose any meaningful limits on practicing the abstract idea. The claim is directed to an abstract idea. Dependent claims 3, 5, 6, 8, 11, and 13-17, when analyzed as a whole are held to be patent ineligible under 35 U.S.C. 101 because the additional recited limitations fail to establish that the claims are not directed to an abstract idea. For example, the dependent claims recite providing feedback information to adjust setting for a device, type of feedback information processing, such as questionnaire data, collecting data using the implementation manager. Since these claims are directed to an abstract idea, the Office must determine whether the remaining limitations “do significantly more” than describe the abstract idea. Part II. Determine whether any Element, or Combination, Amounts to“Significantly More” than the Abstract Idea itself Under Part II, the steps of the claim, when considered individually and as an ordered combination, do not improve another technology or technical field, do not improve the functioning of the computer itself, and are not enough to qualify as "significantly more". For example, the steps require no more than a conventional computer to perform generic computer functions. As stated above, the terminal and database are recited at a high-level of generality such that it amounts to no more than mere instructions to apply the exception using a generic computer component. Therefore, based on the two-part Mayo analysis, there are no meaningful limitations in the claim that transform the exception into a patent eligible application such that the claim amounts to significantly more than the exception itself. Claims 1, 3, 5, 6, 8, 9, 11, and 13-17 , when considered individually and as an ordered combination, are rejected as ineligible subject matter under 35 U.S.C. 101. Dependent claims 3, 5, 6, 8, 11, and 13-17, when analyzed as a whole, are held to be patent ineligible under 35 U.S.C. 101 because the additional claims do no recite significantly more than an abstract idea. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHINYERE MPAMUGO whose telephone number is (571)272-8853. The examiner can normally be reached Monday-Friday, 9am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kambiz Abdi can be reached at (571) 272-6702. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHINYERE MPAMUGO/Primary Examiner, Art Unit 3685
Read full office action

Prosecution Timeline

Show 5 earlier events
Jan 22, 2026
Response Filed
Jun 09, 2026
Final Rejection mailed — §101
Aug 10, 2026
Response after Non-Final Action
Aug 10, 2026
Response after Non-Final Action
Aug 17, 2026
Response after Non-Final Action
Aug 20, 2026
Request for Continued Examination
Aug 22, 2026
Response after Non-Final Action
Sep 21, 2026
Non-Final Rejection mailed — §101 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12770733
Health Monitoring System
2y 1m to grant Granted Oct 20, 2026
Patent 12770735
System for Remote Guidance of Medical Procedures
1y 8m to grant Granted Oct 20, 2026
Patent 12758346
BODY-WEARABLE MEDICAL DEVICE WITH A SEALING ELEMENT
2y 2m to grant Granted Oct 13, 2026
Patent 12749572
ELECTROCARDIOGRAPHIC SIGNAL ANALYSIS SYSTEM
2y 0m to grant Granted Sep 29, 2026
Patent 12727830
DATA ANALYSIS BASED METHODS AND SYSTEMS FOR OPTIMIZING INSERTION OF A MEDICAL INSTRUMENT
3y 10m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
29%
Grant Probability
56%
With Interview (+26.9%)
3y 9m (~1y 8m remaining)
Median Time to Grant
High
PTA Risk
Based on 350 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month